Please assess the completion status of the following clinical trial:

Trial Title: Impact of Fever Prevention in Brain Injured Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Admitted with a primary neurological diagnosis of ischemic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage~2. Prior to onset of acute symptoms, was considered functionally independent (mRS 0-2)~3. Meets disease-specific criteria~Exclusion Criteria:~1. Fever (≥38°C) prior to study enrollment~2. Pre-existing neurological, psychiatric, or other condition that would confound neurological assessment or would make it difficult to accurately assess neurologic and/or functional outcome~3. Has a pre-morbid condition with poor likelihood of survival to 6 months~4. Has a pre-morbid mRS ≥3~5. Diagnosed with brain death~6. Is undergoing therapeutic hypothermia therapy~7. Has sustained neurological injury felt to be catastrophic with little chance of recovery~8. Has a skin condition in which the use of the ArcticGel Pads is contraindicated (i.e., skin that has signs of ulceration, burns, hives, or rash)~9. Has poor skin integrity or poor tissue perfusion~10. Participation in a concurrent investigational / interventional study (medical device or drug)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Fever Prevention (Type: EXPERIMENTAL): Fever will be prevented using a surface targeted temperature management system
- Standard Care (Type: ACTIVE_COMPARATOR): Standard care in which fever may spontaneously develop

Based on this trial design, predict the completion outcome and termination type (if applicable).